{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:38:00Z","timestamp":1781156280427,"version":"3.54.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bulcan.2025.11.004","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:37:28Z","timestamp":1768336648000},"page":"352-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nouvelles approches th\u00e9rapeutiques dans les tumeurs d\u2019Ewing\u00a0: possibilit\u00e9s et d\u00e9fis"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-3986","authenticated-orcid":false,"given":"Sarah","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Helfre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Philippe-Chomette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Pannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Cyrta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.11.004_bib0335","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3\u00a0trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0340","doi-asserted-by":"crossref","first-page":"e28844","DOI":"10.1002\/pbc.28844","article-title":"Prognostic and therapeutic factors influencing the clinical outcome of metastatic Ewing sarcoma family of tumors: a retrospective report from the Japan Ewing Sarcoma Study Group","volume":"68","author":"Umeda","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0345","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99\u00a0trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0350","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.bulcan.2024.01.014","article-title":"[Extra-pulmonary metastatic Ewing sarcoma: the French GroupOs diagnostic and therapeutic recommendations]","volume":"112","author":"Winter","year":"2025","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0355","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2017.08.020","article-title":"Identification of patients with localized Ewing sarcoma at higher risk for local failure: a report from the Children's Oncology Group","volume":"99","author":"Ahmed","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0360","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cncr.29065","article-title":"Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group","volume":"121","author":"DuBois","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13569-020-00144-6","article-title":"Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma","volume":"10","author":"Gerrand","year":"2020","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0370","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0375","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2\u00a0trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0380","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41416-023-02413-9","article-title":"Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study","volume":"129","author":"Duffaud","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0385","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cam4.5044","article-title":"A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024\u00a0trial results","volume":"12","author":"Attia","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0390","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1200\/JCO.2019.37.15_suppl.11007","article-title":"Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma","volume":"37","author":"McCabe","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0395","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3\u00a0trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0400","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2009-11-251231","article-title":"Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs","volume":"115","author":"Nakahara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0405","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0149-2918(08)80059-8","article-title":"Metronomic etoposide\/cyclophosphamide\/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study","volume":"30","author":"Andr\u00e9","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0410","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pbc.24328","article-title":"A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children's Oncology Group (COG) Phase II study NCT00061893","volume":"60","author":"Felgenhauer","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.07.004","article-title":"Natural killer cells can exert a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors","volume":"40","author":"P\u00e9rez-Mart\u00ednez","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0420","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1023\/A:1026539908115","article-title":"Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors","volume":"11","author":"Burdach","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0425","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41409-020-01200-x","article-title":"No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease","volume":"56","author":"Thiel","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0430","article-title":"A single center experience with haploidentical stem cell transplantation for pediatric patients with advanced-stage malignant solid tumors","volume":"8","year":"2023","journal-title":"Ann Case Rep"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0435","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0440","doi-asserted-by":"crossref","first-page":"e4932","DOI":"10.1371\/journal.pone.0004932","article-title":"The Oncogenic EWS-FLI1\u00a0Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function","volume":"4","author":"Guillon","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0445","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","article-title":"EWS-FLI1\u00a0utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma","volume":"26","author":"Riggi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0450","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/2159-8290.CD-13-1037","article-title":"The genomic landscape of pediatric Ewing sarcoma","volume":"4","author":"Crompton","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0455","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nm.1983","article-title":"A small molecule blocking oncogenic protein EWS-FLI1\u00a0interaction with RNA helicase A inhibits growth of Ewing's sarcoma","volume":"15","author":"Erkizan","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00020","article-title":"Open-label, multicenter, phase I\/II, first-in-human trial of TK216: a first-generation EWS::FLI1\u00a0fusion protein antagonist in Ewing sarcoma","author":"Meyers","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0465","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-13-0901","article-title":"Dual targeting of EWS-FLI1\u00a0activity and the associated DNA damage response with Trabectedin and SN38\u00a0Synergistically Inhibits Ewing Sarcoma Cell Growth","volume":"20","author":"Grohar","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0470","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1172\/JCI114910","article-title":"Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor","volume":"86","author":"Yee","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0475","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","article-title":"EWS\/FLI-1\u00a0silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3","volume":"24","author":"Prieur","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0480","first-page":"4127","article-title":"Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice","volume":"58","author":"Scotlandi","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0485","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pbc.21450","article-title":"Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1\u00a0receptor by the pediatric preclinical testing program","volume":"50","author":"Kolb","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0490","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.2011.37.2359","article-title":"Phase II study of ganitumab, a fully human anti\u2013type-1\u00a0insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors","volume":"30","author":"Tap","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0495","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.22.01815","article-title":"Randomized phase III trial of ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma: a report from the Children's Oncology Group","volume":"41","author":"DuBois","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0500","doi-asserted-by":"crossref","first-page":"30178","DOI":"10.18632\/oncotarget.4903","article-title":"Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4\u00a0pathway inhibition in Ewing sarcoma","volume":"6","author":"Kennedy","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0505","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1002\/cam4.6208","article-title":"Phase 2\u00a0trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma","volume":"12","author":"Shulman","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0510","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-18-0372","article-title":"A combination CDK4\/6\u00a0and IGF1R inhibitor strategy for Ewing sarcoma","volume":"25","author":"Guenther","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0515","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1\u00a0inhibition as a targeted strategy to treat Ewing's sarcoma","volume":"72","author":"Brenner","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0520","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/1471-2407-14-813","article-title":"Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy","volume":"14","author":"Choy","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0525","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.33349","article-title":"SARC025\u00a0arms 1\u00a0and 2: a phase 1\u00a0study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma","volume":"127","author":"Chugh","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0530","doi-asserted-by":"crossref","first-page":"e28073","DOI":"10.1002\/pbc.28073","article-title":"Phase 1\/2\u00a0trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a Children's Oncology Group Phase 1\u00a0Consortium study (ADVL1411)","volume":"67","author":"Schafer","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0535","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-016-0278-x","article-title":"Programmed cell death-1\u00a0blockade in recurrent disseminated Ewing sarcoma","volume":"9","author":"McCaughan","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0540","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2\u00a0trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0545","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2\u00a0trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0550","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children's Oncology Group Study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0555","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-03-0038","article-title":"Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1\u00a0and May Represent an Independent Predictor of Survival in Ewing's Sarcoma","volume":"10","author":"Fuchs","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0560","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2006.01.063","article-title":"Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma","volume":"42","author":"Kreuter","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0565","doi-asserted-by":"crossref","first-page":"e28313","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2\u00a0as a target for CAR T cell therapy of Ewing sarcoma","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0570","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.seminoncol.2014.07.003","article-title":"GD2-targeted immunotherapy and radioimmunotherapy","volume":"41","author":"Dobrenkov","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0575","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01\u00a0for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0580","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/imt-2020-0341","article-title":"Targeting the tumor microenvironment of Ewing sarcoma","volume":"13","author":"Morales","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0585","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0590","doi-asserted-by":"crossref","first-page":"e14302","DOI":"10.1097\/MD.0000000000014302","article-title":"Integrative analysis reveals driver long non-coding RNAs in osteosarcoma","volume":"98","author":"Luo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0171-2985(99)80029-1","article-title":"Monomorphic HLA class I-(non-A, non-B) expression on Ewing's tumor cell lines, modulation by TNF-\u03b1 and IFN-\u03b3","volume":"200","author":"Borowski","year":"1999","journal-title":"Immunobiology"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0600","first-page":"8513","article-title":"Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression","volume":"61","author":"Geiger","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0605","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/mpo.1303","article-title":"Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2\u00a0in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study","volume":"38","author":"Dagher","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0610","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-07-4065","article-title":"A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas","volume":"14","author":"Mackall","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0615","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/mt.2015.43","article-title":"Pilot trial of FANG immunotherapy in Ewing's sarcoma","volume":"23","author":"Ghisoli","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0620","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1158\/1078-0432.CCR-22-2292","article-title":"Pilot study of recurrent Ewing's sarcoma management with vigil\/temozolomide\/irinotecan and assessment of circulating tumor (ct) DNA","volume":"29","author":"Anderson","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0625","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.2005.02.081","article-title":"Ewing sarcomas with p53\u00a0mutation or p16\/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse","volume":"23","author":"Huang","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0630","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/pbc.25340","article-title":"Tumoral TP53\u00a0and\/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group","volume":"62","author":"Lerman","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0635","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","article-title":"Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2\u00a0and TP53\u00a0mutations","volume":"4","author":"Tirode","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0640","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-018-0456-5","article-title":"Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma","volume":"12","author":"Cheng","year":"2019","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0645","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/onc.2011.317","article-title":"1q gain and CDT2\u00a0overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma","volume":"31","author":"Mackintosh","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0650","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6600332","article-title":"Prognostic impact of chromosomal aberrations in Ewing tumours","volume":"86","author":"Hattinger","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0655","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.31919","article-title":"Risk stratification by somatic mutation burden in Ewing sarcoma","volume":"125","author":"Liu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.11.004_bib0330","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cam4.3712","article-title":"Systematic review of phase-I\/II trials enrolling refractory and recurrent Ewing sarcoma: actual knowledge and future directions to optimize the research","volume":"10","author":"Felix","year":"2021","journal-title":"Cancer Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:15:09Z","timestamp":1773177309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125005260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0007455125005260"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles approches th\u00e9rapeutiques dans les tumeurs d\u2019Ewing\u00a0: possibilit\u00e9s et d\u00e9fis","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}